Drug survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis

British Journal of Dermatology

Volumn 172, Issue 6, 2015, Pages 1621-1627

  Van Der Schaft, J ^a   Politiek, K ^b   Van Den Reek, J M P A ^c   Christoffers, W A ^b   Kievit, W ^c   De Jong, E M G J ^c   Bruijnzeel Koomen, C A F M ^a   Schuttelaar, M L A ^b   De Bruin Weller, M S ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYCLOSPORIN A; HEMOGLOBIN; IMMUNOSUPPRESSIVE AGENT; CYCLOSPORIN; DERMATOLOGICAL AGENT;

ADULT; ARTICLE; ATOPIC DERMATITIS; COHORT ANALYSIS; CONJUNCTIVITIS; CREATININE BLOOD LEVEL; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SURVIVAL; DRUG USE; DRUG WITHDRAWAL; DYSPNEA; EDEMA; ERYSIPELAS; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HAZARD RATIO; HEART PALPITATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERPLASIA; HYPERTENSION; HYPERTRICHOSIS; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI VARICELLIFORM ERUPTION; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; MUSCLE WEAKNESS; MYALGIA; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENESCENCE; SIDE EFFECT; SURVIVAL; SURVIVAL RATE; TREATMENT DURATION; TREMOR; VISUAL IMPAIRMENT; AGE; CLINICAL TRIAL; DERMATITIS, ATOPIC; DRUG ADMINISTRATION; DRUG SUBSTITUTION; LONG TERM CARE; MULTICENTER STUDY; TREATMENT OUTCOME;

ADULT; AGE FACTORS; CYCLOSPORINE; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; FEMALE; HUMANS; LONG-TERM CARE; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84930377382     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13730     Document Type: Article

References (19)

1. Ring J, Alomar A, Bieber T, et al,. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol 2012; 26: 1176-93.
2. Schmitt J, Schmitt N, Meurer M,. Cyclosporin in the treatment of patients with atopic eczema-a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2007; 21: 606-19.
3. Rothwell PM,. External validity of randomised controlled trials: 'To whom do the results of this trial apply?'. Lancet 2005; 365: 82-93.
4. Burden AD,. Drug survival rates for tumour necrosis factor-alpha antagonists in psoriasis. Br J Dermatol 2011; 164: 940-1.
5. Wolfe F,. The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin Rheumatol 1995; 9: 619-32.
6. Hanifin J, Rajka G,. Diagnostic features of atopic dermatitis. Acta Derm Venereol 1980; 92: 44-7.
7. Williams HC, Burney PG, Pembroke AC, Hay RJ,. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation. Br J Dermatol 1994; 131: 406-16.
8. Neovius M, Arkema EV, Olsson H, et al,. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis 2015; 74: 354-60.
9. Marchesoni A, Zaccara E, Gorla R, et al,. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 2009; 1173: 837-46.
10. van den Reek JMPA, van Lümig PPM, Driessen RJB, et al,. Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis. Br J Dermatol 2014; 170: 415-25.
11. Gniadecki R, Kragballe K, Dam TN, Skov L,. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 2011; 164: 1091-6.
12. de Groot M, Appelman M, Spuls PI, et al,. Initial experience with administration of etanercept in psoriasis. Br J Dermatol 2006; 155: 808-14.
13. van Lümig PPM, Driessen RJB, Boezeman JBM, et al,. Long-term efficacy of etanercept for psoriasis in daily practice. Br J Dermatol 2012; 166: 445-7.
14. Elkayam O, Pavelka K,. Biologic registries in rheumatology: lessons learned and expectations for the future. Autoimmun Rev 2012; 12: 329-36.
15. van der Lem R, van der Wee NJA, van Veen T, Zitman FG,. Efficacy versus effectiveness: a direct comparison of the outcome of treatment for mild to moderate depression in randomized controlled trials and daily practice. Psychother Psychosom 2012; 81: 226-34.
16. Haeck IM, Knol MJ, Ten Berge O, et al,. Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. J Am Acad Dermatol 2011; 64: 1074-84.
17. Jones J, Gorkin L, Lian J, et al,. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BMJ 1995; 311: 293-5.
18. Andrade SE, Walker AM, Gottlieb LK, et al,. Discontinuation of antihyperlipidaemic drugs-do rates reported in clinical trials reflect rates in primary care settings. N Engl J Med 1995; 332: 1125-31.
19. van Onzenoort HA, Menger FE, Neef C, et al,. Participation in a clinical trial enhances adherence and persistence to treatment: a retrospective cohort study. Hypertension 2011; 58: 573-8.